RecallRadar

FDA Drug recall D-0149-2017

BuPROPion Hydrochloride Extended-Release Tablets, USP (XL) 300 mg, Rx Only, 500-count bottles, Manufactured by Cadila Healthcare Ltd

On 2016-11-30 the FDA classified a Class III recall of BuPROPion Hydrochloride Extended-Release Tablets, USP (XL) 300 mg, Rx Only, 500-count bottles, Manufactured by Cadila Healthcare Ltd by Zydus Pharmaceuticals Usa, citing failed Dissolution Specifications: Product did not meet dissolution specification at an intermediate time point.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0149-2017
ClassificationClass III
Statusterminated
Initiated2016-08-03
Published2016-11-30
Last updated2026-09-13 11:51 UTC
CompanyZydus Pharmaceuticals Usa
DistributionUS

Product

BuPROPion Hydrochloride Extended-Release Tablets, USP (XL) 300 mg, Rx Only, 500-count bottles, Manufactured by Cadila Healthcare Ltd. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA inc. Pennington, NJ 08534, NDC 68382-354-05

Reason

Failed Dissolution Specifications: Product did not meet dissolution specification at an intermediate time point.

Identifiers

ndc68382-354-06
ndc68382-354-16
ndc68382-354-05
ndc68382-354-10
ndc68382-353-06
ndc68382-353-16
ndc68382-353-05
ndc68382-353-10
code_infoLot #: MR3365, Exp. Feb 17

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0149-2017%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.